The Wall Street Journal99d agoneutral
Health Care Roundup: Market TalkFind insight on the deal between Hengrui Pharmaceuticals and Bristol Myers Squibb and more in the latest Market Talks covering the health care sector.
Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
238last 24h
1541last 7d
258● bullish (7d)
159● bearish (7d)
205publishers
The Wall Street Journal99d agoneutral
Bristol-Myers Squibb and China’s Hengrui Pharma Forge Tie-UpU.S. pharma giant Bristol-Myers Squibb has struck a partnership and licensing deal with Chinese drugmaker Hengrui, in a deal that could worth more than $15 billion.
The Wall Street Journal99d agoneutral
Bristol-Myers Squibb and China’s Hengrui Pharma Forge Tie-UpU.S. pharma giant Bristol-Myers Squibb has struck a partnership and licensing deal with Chinese drugmaker Hengrui, in a deal that could worth more than $15 billion.
MarketBeat102d agoneutral
Xenon Pharmaceuticals Q1 Earnings Call HighlightsXenon Pharmaceuticals (NASDAQ:XENE) said it is preparing to submit a new drug application to the U.S. Food and Drug Administration in the third quarter of 2026 for azetukalner, its investigational anti-seizure medicine, after reporting positive Phase 3 data in focal onset seizures during the first q